红蓝光联合0.1%阿达帕林凝胶治疗寻常痤疮85例临床观察  被引量:20

Clinical Observation of Red and Blue Light Combined with 0. 1% Adapalene Gel in the Treatment of 85 Cases with Acne Vulgaris

在线阅读下载全文

作  者:吴海斌[1] 孙辉[1] 石家宴[1] 杨义成[1] 付敏[1] 

机构地区:[1]广州医科大学附属深圳沙井人民医院皮肤科,广东深圳518104

出  处:《中国皮肤性病学杂志》2014年第5期546-547,550,共3页The Chinese Journal of Dermatovenereology

摘  要:目的评价红蓝光联合0.1%阿达帕林凝胶治疗寻常痤疮的临床疗效。方法将入选的163例寻常痤疮患者随机分为两组,治疗组(85例)予红蓝光联合0.1%阿达帕林凝胶外搽治疗,对照组(78例)仅予0.1%阿达帕林凝胶治疗,比较两组患者的临床疗效和不良反应。结果治疗4周时,治疗组有效率58.82%,对照组29.49%;治疗8周时有效率分别为84.71%和60.26%,差异均有统计学意义(P均<O.001)。治疗组不良反应发生率5.88%,对照组3.85%,差异无统计学意义(P>0.05)。结论红蓝光联合0.1%阿达帕林凝胶外搽治疗痤疮安全而有效。Objective To study the clinical effect of the combined therapy of red and blue light with 0. 1% adapalene gel in the treatment of acne vulgaris. Methods A total of 163 patients with acne vulgaris were divided into treatment group (85 cases) and control group (78 cases) randomly. The treatment group were treated with red and blue light combined with 0. 1% adapalene gel, and the control group were treated only with 0. 1% adapalene gel. The effective rate and the adverse reaction rate were evaluated at the times of 4, 8 weeks. Results At the time of 4 weeks, the effective rate were 58.82% in the treatment group and 29.49% in the control group, and there were significant differences between them (P 〈 0. 001 ). At the time of 8 weeks, the effective rate were 84. 71% in the treatment group and 60. 26% in the control group, and there were significant differences between them (P 〈 0. 001 ). The adverse reaction rate were 5.88% in the treat- ment group, 3. 85% in the control group respectively, and there were no significant differences between them (P 〉 O. 05 ). Conclusion The combined therapy of red and blue light with 0. 1% adapalene gel in the treatment of ache is not only effective but also safe.

关 键 词:红蓝光 阿达帕林凝胶 痤疮 临床观察 

分 类 号:R758.733[医药卫生—皮肤病学与性病学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象